Search ↗

Comparison

BPC-157 vs GHK-Cu

Both are healing & repair, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, GHK-Cu is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

BPC-157 GHK-Cu
Class Healing & repair Healing & repair
Evidence Animal models only Clinical trials
Human trials None published ~15
Half-life ~4 hours ~30 minutes (systemic)
Reported range 200-500 mcg 1-2 mg
Frequency 1-2x daily, often near the injury site Daily topical, or subcutaneous in research protocols
Routes Subcutaneous, Oral, Intramuscular Topical, Subcutaneous
FDA approved No No
Research use only Yes No
Banned in sport Yes No
Studied for Tendon and ligament injury research, Gastrointestinal healing research, Soft tissue repair Skin repair and anti-ageing, Wound healing, Hair follicle stimulation
Reported side effects Injection-site reactions, Transient nausea, Headache, Dizziness Local irritation, Transient redness, Injection-site reactions

BPC-157

BPC-157 is a stable 15-amino-acid sequence derived from body protection compound, a protein found in human gastric juice. Animal work reports accelerated healing across tendon, ligament, muscle, bone and gastrointestinal tissue, with proposed mechanisms including upregulation of VEGF-driven angiogenesis, modulation of the nitric oxide system, and increased fibroblast migration and growth-factor receptor expression. The evidence base is almost entirely rodent. No adequately powered human trial has been published, which is the central fact about this compound and should lead every page about it.

GHK-Cu

GHK is a tripeptide present in human plasma that declines markedly with age, and it binds copper(II) with high affinity to form GHK-Cu. The complex modulates expression of a large set of genes involved in tissue remodelling, stimulating collagen, elastin and glycosaminoglycan synthesis while influencing antioxidant and anti-inflammatory pathways. Its dermatological evidence is comparatively strong and includes controlled human trials; the systemic injectable use is far less supported.

BPC-157 vs GHK-Cu: common questions

What is the difference between BPC-157 and GHK-Cu?

Both are healing & repair. BPC-157: A synthetic pentadecapeptide derived from a gastric protein, and the most searched compound in the peptide category. GHK-Cu: A naturally occurring copper-binding tripeptide with the strongest human evidence base of any compound in the healing group, mostly topical.

Which has stronger evidence, BPC-157 or GHK-Cu?

GHK-Cu has the stronger evidence base (clinical trials, about 15 human studies) compared with BPC-157 (animal models only).

Are BPC-157 and GHK-Cu FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 9941957) ↗ · structure, identifiers, synonyms
  2. WADA Prohibited List ↗ · current year
  3. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  4. CAS Registry Number 137525-51-0 ↗ · chemical identity
  5. PubChem compound record (CID 139035031) ↗ · structure, identifiers, synonyms
  6. CAS Registry Number 89030-95-5 ↗ · chemical identity

Published literature

  1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.Cell Tissue Res 2019.PubMed 30915550 · doi:10.1007/s00441-019-03016-8
  2. Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.Curr Pharm Des 2018.PubMed 29998800 · doi:10.2174/1381612824666180712110447
  3. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  5. DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?.Arthroscopy 2025.PubMed 39265666 · doi:10.1016/j.arthro.2024.09.005
  6. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  7. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  8. Seiwerth S, Brcic L, Vuletic LB, et al.. BPC 157 and blood vessels.Curr Pharm Des 2014.PubMed 23782145 · doi:10.2174/13816128113199990421
  9. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.Int J Mol Sci 2018.PubMed 29986520 · doi:10.3390/ijms19071987
  10. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.Biomed Res Int 2015.PubMed 26236730 · doi:10.1155/2015/648108
  11. Ogórek K, Nowak K, Wadych E, et al.. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?.Molecules 2025.PubMed 39795193 · doi:10.3390/molecules30010136
  12. Pickart L. The human tri-peptide GHK and tissue remodeling.J Biomater Sci Polym Ed 2008.PubMed 18644225 · doi:10.1163/156856208784909435

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.